外泌体液体活检在肿瘤中的应用:机遇与挑战
本文综述了外泌体及其他细胞外囊泡作为肿瘤液体活检平台的机遇与挑战,并与循环肿瘤DNA及循环肿瘤细胞进行对比。外泌体携带DNA、RNA、蛋白、脂质、糖结构与代谢物,表面分子可提示组织来源,且在血浆和尿液中稳定性好。首个基于外泌体RNA的前列腺癌检测已辅助超过50 000名患者的决策过程,并被纳入NCCN早期前列腺癌检测指南。
要点
- 外泌体携带肿瘤来源核酸、蛋白与代谢物,表面分子可用于溯源分选。
- 外泌体在血浆和尿液中稳定性好,疾病早期即可分离用于临床评估。
- 首个外泌体RNA前列腺癌检测已辅助超50 000名患者决策并纳入NCCN指南。
核心结论
- 外泌体液体活检在肿瘤生物标志物研究与临床落地中兼具潜力和挑战,可作为循环肿瘤DNA与循环肿瘤细胞的互补平台。
研究设计与样本
- 本文为综述,围绕外泌体及其他细胞外囊泡在肿瘤液体活检中的应用,并与循环肿瘤DNA和循环肿瘤细胞进行对照讨论。
主要发现
- 外泌体由包括癌细胞在内的细胞释放入周围生物液体,内含DNA、RNA、蛋白、脂质、糖结构和代谢物。
- 外泌体表面携带的分子可提供来源线索,使分选囊泡类型和富集组织特异性来源特征成为可能。
- 外泌体是细胞间通讯系统的一部分,癌细胞常将其作为生物信使以利于自身生长。
- 外泌体在血浆和尿液等生物液体中稳定性突出,疾病早期即可分离用于临床评估。
- 首个基于外泌体RNA的前列腺癌检测已帮助超过50 000名患者进行决策,并被纳入NCCN早期前列腺癌检测指南。
临床怎么用
- 可将外泌体液体活检用于肿瘤早期检测、治疗分层以及残留病灶与复发监测的探索性应用。
- 开展外泌体检测时需结合循环肿瘤DNA与循环肿瘤细胞结果综合解读,并关注其与组织来源的对应关系。
局限性
- 外泌体液体活检在肿瘤生物标志物临床落地中仍面临挑战,具体局限本文以综述形式讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a boom for a variety of applications. There are significant efforts to utilize liquid biopsies in cancer for early detection and treatment stratification, as well as residual disease and recurrence monitoring. Although most efforts have used circulating tumor cells and circulating tumor DNA for this purpose, exosomes and other extracellular vesicles have emerged as a platform with potentially broader and complementary applications. Exosomes/extracellular vesicles are small vesicles released by cells, including cancer cells, into the surrounding biofluids. These exosomes contain tumor-derived materials such as DNA, RNA, protein, lipid, sugar structures, and metabolites. In addition, exosomes carry molecules on their surface that provides clues regarding their origin, making it possible to sort vesicle types and enrich signatures from tissue-specific origins. Exosomes are part of the intercellular communication system and cancer cells frequently use them as biological messengers to benefit their growth. Since exosomes are part of the disease process, they have become of tremendous interest in biomarker research. Exosomes are remarkably stable in biofluids, such as plasma and urine, and can be isolated for clinical evaluation even in the early stages of the disease. Exosome-based biomarkers have quickly become adopted in the clinical arena and the first exosome RNA-based prostate cancer test has already helped >50 000 patients in their decision process and is now included in the National Comprehensive Cancer Network guidelines for early prostate cancer detection. This review will discuss the advantages and challenges of exosome-based liquid biopsies for tumor biomarkers and clinical implementation in the context of circulating tumor DNA and circulating tumor cells.
引用
- Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021. PMID: 33548389. doi:10.1016/j.annonc.2021.01.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。